Key result
PAH-specific drugs show potential to convert inoperable congenital heart disease patients to operable status.
Why the study?
The decision to repair congenital heart defects in patients with raised pulmonary vascular resistance is complex due to risks associated with high pulmonary vascular resistance and uncertain operability.
Can pulmonary arterial hypertension-specific drugs convert patients with 'inoperable' congenital heart defects to an operable status?
Can pulmonary arterial hypertension-specific drugs convert patients with 'inoperable' congenital heart defects to an operable status?
This review highlights the potential role of PAH-specific therapies in modifying pulmonary vascular resistance to enable surgical repair in patients with previously inoperable congenital heart defects.
No takes yet. Share an insight, caveat, or question.
PAH-specific drugs may enable operability reassessment in select inoperable CHD; leaves open need for prospective trials before practice change.
Beghetti et al. (2012) conducted a review in Congenital heart defects with pulmonary arterial hypertension. Pulmonary arterial hypertension-specific drugs was evaluated. This review explores whether pulmonary arterial hypertension-specific drugs can convert patients with congenital heart defects deemed inoperable due to pulmonary vascular disease to an operable status.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: